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ABSTRACT
Familial hemophagocytic lymphohistiocytosis (FHL) is a rare fatal autosomal recessive disorder of immune dysregulation. 
The disease presents most commonly in the first year of life; however, symptomatic presentation throughout childhood 
and adulthood has also been identified. Biallelic mutation in the perforin gene is present in 20%–50% of all cases of 
FHL. Secondary hemophagocytic lymphohistiocytosis (HLH) in association with hematological malignancies is known; 
however, whether mutations in HLH-associated genes can be associated with FHL and hematolymphoid neoplasms is 
not well documented. Also, Epstein–Barr-virus- (EBV) positive systemic T-cell lymphoproliferative disease (SE-LPD) in the 
setting of FHL is not clearly understood. Here, we present the case of a young boy who presented with typical features of 
childhood FHL harboring the perforin gene (PRF1) mutation, and had SE-LPD diagnosed on autopsy, along with evidence 
of recent EBV infection. The patient expired due to progressive disease. Five siblings died in the second or third decade 
of life with undiagnosed disease. Genetic counseling was provided to the two surviving siblings and parents, but they 
could not afford genetic testing. One surviving sibling has intermittent fever and is on close follow-up for possible bone 
marrow transplantation. 
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INTRODUCTION
Familial hemophagocytic lymphohistiocytosis 
(FHL) is a rare fatal autosomal recessive disorder of 
immune dysregulation characterized by genetic defects 
in cytotoxic cell function, resulting in uncontrolled 
T-cell and macrophage infiltration in multiple organs 
causing irreversible damage.1 The disease usually 
presents in the first year of life; however, symptomatic 
presentation in childhood and even adulthood has also 
been identified.2,3 Siblings have onset of disease at 
approximately the same age, with similar presentation 
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and outcome.3 Childhood FHL typically presents 
with liver dysfunction, neurological involvement, 
and bone marrow hemophagocytosis. Rash and 
lymphadenopathy are less common.4 No specific 
clinical or histological findings distinguish secondary 
hemophagocytic lymphohistiocytosis (HLH) from 
FHL; however, genetic work-up often aids in the 
distinction between both. Diagnosis is based on 
clinical criteria, and is confirmed by molecular genetic 
testing.4 Secondary HLH associated with hematological 
malignancies is well known.5 However, it is not well 
studied whether mutations in HLH-associated genes 
can result in both malignancy (i.e. systemic T-cell 
lymphoproliferative disorders [SE-LPDs]) and FHL.6 Four 
genetic loci have been identified in FHL, with biallelic 
mutations in the perforin gene (PRF1) being present 
in 20%–40% of all FHL cases worldwide.4 All are part 
of the PRF1-dependent cytotoxic pathway leading 
to the abnormal function of NK-cells and cytotoxic 
T-lymphocytes.7,8 Studies have shown that perforin 
and other mutations present in FHL are also present 
in a proportion of patients diagnosed with lymphomas 
who share clinical characteristics of HLH.9,10 Here, we 
present the case of young boy with typical features of 
childhood FHL and systemic T-cell lymphoproliferative 
disorder along with evidence of recent Epstein–Barr 
virus (EBV) infection confirmed on autopsy. He had a 
significant family history of the death of five siblings in 
the second to third decades of life with undiagnosed 
disease. He had a prior difficult clinical course and 
presented a diagnostic challenge to both clinicians 
and pathologists.
CASE REPORT
A 15-year-old boy from Nepal presented to the 
medicine out-patient department with a history of 
high-grade fever associated with anorexia and weight 
loss (10 kg) for 5 months. There were no specific 
localizing symptoms, history of travel, exposure to 
ill-contacts or high-risk behavior. He had been treated 
with oral anti-tuberculosis therapy (3 weeks) by a local 
physician due to non-relenting fever. His past medical 
history was non-contributory except for fever and 
jaundice 3 years ago, which responded to conservative 
management. The patient was the youngest of eight 
siblings, born of a non-consanguineous marriage. 
The family history was significant for the death of five 
siblings due to undiagnosed illnesses with prolonged 
fever, two of whom also had jaundice (Figure 1).
All deceased siblings succumbed between the first 
and third decades of life. Anti-tuberculosis therapy had 
been initiated in three of these siblings in the absence 
of conclusive evidence of tuberculosis. The two surviving 
elder siblings also had a history of undiagnosed fever with 
jaundice, with spontaneous recovery in a few weeks. 
The details of treatment regimens and investigations of 
the deceased siblings were unavailable. On admission, our 
patient was conscious and oriented, had fever (38.3°C), 
tachycardia (pulse rate 110/min) and hypotension 
(blood pressure 95/60 mmHg). His respiratory rate was 
20/min with 96% oxygen saturation on room air. Pallor 
and icterus were present. There was no rash, clubbing, 
cyanosis, or edema. The abdominal examination revealed 
hepatosplenomegaly. Initial investigations revealed severe 
pancytopenia with deranged liver function tests (Table 1).
In view of the possibility of drug-induced liver 
injury, anti-tuberculosis therapy was modified, and 
empirical antibiotics were given according to the 
febrile neutropenia regimen. The blood work-up 
revealed hyperferritinemia (3,346 ng/mL [reference 
range (RR): 20–250 ng/ml]), hypertriglyceridemia 
(33,658.1 mg/dL [RR: <150 mg/dL ]) with raised LDH 
(1,748 U/L [RR: 60–170 Units/L ]). These findings raised 
the suspicion of HLH syndrome and investigations 
to identify the underlying trigger were carried out. 
A high titer of EBV viral-capsid antigen (EBV-VCA) 
immunoglobulin M (IgM) antibody was suggestive 
of an acute EBV infection. Other tests for infection 
Figure 1. Pedigree analysis showing the death of five 
siblings (four sisters and one brother) due to unexplained 
fever and jaundice. The two elder surviving siblings 
also have history of self-resolving fever and jaundice. 
(Solid color: deceased; stripes: diseased; red arrow: 
index patient.).
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revealed sterile blood and urine cultures; negative 
serology for brucellosis, leishmaniasis and enteric fever; 
negative tuberculin skin test; and negative viral and 
autoimmune markers.
A bone marrow biopsy revealed hypercellular 
marrow showing dense histiocytic infiltration with 
evidence of hemophagocytosis as well as an atypical 
T-cell infiltrate. Flow cytometry of bone marrow aspirate 
for malignant cells, staining for acid-fast bacilli, as 
well as cartridge-based nucleic acid amplification test 
(CBNAAT) assay for tuberculosis were negative. A liver 
biopsy showed interface hepatitis. 18FDG-positron 
emission tomography-computed tomography (PET CT) 
scan showed hepatomegaly (22.7 cm) and splenomegaly 
(17.9 cm), which was metabolically active with multiple 
FDG-avid abdominal and pelvic nodes. There was also 
significant FDG uptake in the axial and appendicular 
skeleton and the presence of FDG-avid, hypodense, 
bilateral, thyroid masses (Figure 2).
With the above findings, the possibility of acquired 
HLH secondary to a lymphoproliferative malignancy 
was the best working diagnosis. However, given the 
strong family history, the possibility of FHL was also 
considered. The patient was managed in accordance 
with the HLH-94 protocol with dexamethasone 
and weekly etoposide, along with broad-spectrum 
antibiotics and modified anti-tuberculosis therapy. 
Over the next 10 days, the patient deteriorated with 
continuous fever spikes, worsening liver function 
tests, and pancytopenia. Hepatotoxic drugs were 
discontinued, blood products were transfused, and 
an empirical anti-fungal cover was added. The search 
for an HLA-matched sibling and an unrelated bone 
marrow donor was attempted but was unsuccessful. 
On day 12 of admission, the patient developed Type 1 
respiratory failure with new-onset lung consolidation, 
mandating mechanical ventilation. Antibiotics were 
upgraded for likely hospital-acquired pneumonia. 
The patient succumbed on day 14 of hospitalization 
with refractory shock and renal shutdown.
AUTOPSY FINDINGS
On the opening of the thoracoabdominal cavity, 
there were gross ascites, pleural and pericardial 
effusions, generalized visceral lymphadenopathy, 
marked hepatosplenomegaly, and thyromegaly. On the 
Table 1. Laboratory parameters during hospital stay
Parameter
On 
Admission
Day 10*
Hemoglobin (g/dL) 6.1 5.0
Total leucocyte count (/mm3) 3,400 2,800
polymorphonuclear 38% 35%,
Neutrophils (cells/mm3) 1,340 980
MCV (fl) 75.2 60
MCH (pg) 20 15
MCHC (g/dL) 22.2 15
Platelet count (/mm3) 40,000 9,000
Urea/Creatinine (mg %) 27/0.8 40/2
Bilirubin Total/Direct (mg/dL) 3/2.7 11.5/10.5
AST/ALT (IU/L) 106/44 340/100
ALP (IU/L) 968 1,460
PT/INR 14/1.2 24/1.9
*Days of treatment;  MCV- Mean corpuscular volume, 
MCH- Mean corpuscular hemoglobin, MCHC- Mean corpuscular 
hemoglobin concentration, AST- Aspartate aminotransferase, 
ALT- Alanine aminotransferase, ALP- Alkaline phosphatase, 
PT/INR- Prothrombin time/ International normalized ratio.
Figure 2. 18FDG-PET CT scan (coronal and sagittal images) 
showing hepatomegaly (22.7 cm) and splenomegaly 
(17.9 cm), metabolically active with multiple FDG-avid 
abdominal and pelvic nodes. Significant FDG uptake 
in axial and appendicular skeleton and the presence of 
FDG-avid, hypodense, bilateral, thyroid masses. PET-CT: 
positron emission tomography-computed tomography.
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opening of the cranial cavity, the dura and brain were 
grossly unremarkable, and multiple sections from the 
brain were histologically normal. The gross thyroid 
examination showed a thick and adherent capsule. 
On serial slicing, the thyroid parenchyma was solid 
and firm, with the absence of colloid. The microscopic 
examination depicted a diffuse effacement of the 
follicular architecture with dense T-cell-rich infiltrate 
along with histiocytes destroying the thyroid follicles 
and forming diffuse lymphoepithelial lesions. Infiltrating 
T-cells displayed mild atypia. The follicular rupture was 
present; however, Hürthle cell change was absent. 
The thyroid capsule was thickened, with areas of 
capsular spill extending into the surrounding fat tissue 
(Figure 3).
Infiltrating T-cells showed immunopositivity 
predominantly for CD3 and CD4, and a sprinkling 
pattern of immunoreactivity for CD7, CD8, and CD5. 
CD 20 immunoreactivity was noted in a few of the 
dispersed larger cells. Granzyme and CD 56—the 
markers of activation—were positive in the T-cells. 
EBV-LMP1 staining was present in 2–5 cells/high-power 
field (Figure 4).
On microscopy, the architecture of the lymph 
nodes was maintained; however, sinus histiocytosis 
with evidence of erythrophagocytosis, and the 
presence of sinus T-cell infiltrates were present. 
Occasional multinucleated giant cells were also found 
(Figure 5A–C). Liver sections showed maintained 
architecture with dilated sinusoids and portal 
infiltrates comprised of T-lymphocytes and histiocytes 
(Figure 5D). Sections from the spleen showed a loss 
of lymphoid follicles, marked red pulp congestion, 
T-cell rich lymphoid infiltrates, and dense histiocytosis 
(Figure 6A and 6B).
S e c t i o n s  f r o m  t h e  l u n g  s h o w e d  t h e 
histomorphological features of diffuse lobar pneumonia 
with alveolar exudate rich in histiocytes and T-cells. 
Bone marrow was hypercellular (Figure 7A) with 
near total replacement of normal hematopoietic 
Figure 3. Photomicrographs of the thyroid. A – The capsular spill and infiltrative border (H&E, 100X); B & C – Diffuse 
infiltrate of T-cells destroying the thyroid follicles and forming lymphoepithelial lesions (H&E, 200X & 400X, 
respectively); D – Occasional ruptured follicles were also noted (H&E,100X).
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Figure 4. Photomicrographs of the thyroid. A – The majority of infiltrating lymphocytes stained for CD3 (100X). 
B – CD68 positive histiocytes (200X). C – T-cells immunopositive for granzyme-B (200X). D – EBV-LMP1 staining 
large atypical lymphoid cells (200X).
Figure 5. Photomicrographs of the lymph node (A, B, and C) and liver (D). A – Lymph node architecture maintained 
and marked sinus histiocytosis (H&E,100X). B – Macrophages displaying emperipolesis (blue arrow) and sinus 
histiocytes (red arrow) (H&E, 200X). C – An occasional multinucleated giant cell (H&E, 200X). D – Sinusoidal dilation 
and portal hepatitis comprising T-cells and histiocytes (H&E, 100X).
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elements by sheets of histiocytes admixed with 
T-cells and a few large cells (Figure 7B). T-cells 
and a few interspersed CD20 positive lymphoid 
aggregates (Figure 7C and 7D). Few histiocytes 
displayed hemophagocytosis containing lymphocytes 
and leucocytes (Figure 8). CD68 immunostaining 
demonstrated a predominant histiocytic population 
(Figure 9A).
Immunohistochemistry for EBV-LMP1 and in-situ 
hybridization for EBV-encoded RNA (ISH EBER) was 
positive in a dispersed pattern in the infiltrating 
lymphoid cells (Figure 9B).
Figure 6. Photomicrographs of the spleen. A – Marked red pulp congestion with infiltrates rich in histiocytes and 
T-cells (H&E, 200X). B – CD 68 immunostaining highlights predominant histiocytic infiltration (H&E, 200X).
Figure 7. Photomicrographs of the bone marrow. A – The core of hypercellular bone marrow (H&E, 100X). B – Note 
the near total replacement of normal hematopoietic elements by sheets of histiocytes admixed with T-cells and a 
few large cells (H&E,200X). C – CD3 stain shows a predominant T-cell population (200X). D – Immunostaining for 
CD20 is positive in a few large interspersed B-cells (200X).
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Based on the clinico-histopathological findings, 
a final diagnosis of HLH involving liver, spleen, lymph 
nodes, and bone marrow, with associated EBV-positive 
T-cell lymphoproliferative disorder of thyroid infiltrating 
liver, spleen, lung, and bone marrow was made. Whole 
exome sequencing (next-generation sequencing) 
performed on a bone marrow aspirate sample revealed a 
homozygous missense mutation in exon 3 of the perforin 
gene (PRF1) on chromosome 10 (chr10:72358128G>A) 
(Figure 10). This mutation resulted in the amino acid 
substitution of methionine for threonine at codon 
450 (p.Thr450Met) and was pathogenic for autosomal 
recessive familial hemophagocytic lymphohistiocytosis-2 
(FHL-2). Genetic counseling was provided for the two 
surviving siblings and parents, but they could not afford 
genetic testing.
Figure 8. Photomicrographs of the bone marrow showing 
dense histiocytosis with evidence of hemophagocytosis. 
The black arrows show hemophagocytic histiocytes 
containing lymphocytes and leucocytes (H&E 20X). (Inset: 
multinucleated macrophages showing hemophagocytosis 
[arrowheads; H&E 40X]).
Figure 9. Photomicrographs of the bone marrow. A – Histiocytes immunopositive for CD68 (200X). B – EBV LMP-1 
immunopositive in atypical lymphoid cells (200X).
Figure 10. Mutation analysis: Whole exome sequencing performed on the bone marrow aspirate sample revealed a 
homozygous missense mutation in exon 3 of the perforin gene (PRF1) on chromosome 10 (chr10:72358128G>A).
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DISCUSSION
In the index case of FHL in this family, clinical 
criteria for the diagnosis of FHL were met and there 
were similar presentations in five siblings who were 
undiagnosed. Pathogenic mutation in the PRF1 gene 
was identified which explains the clinical manifestations. 
Diagnosing FHL can be a challenge when the disease 
presents in the first sibling with a conglomerate of 
non-specific signs and symptoms mimicking many 
infectious and autoimmune diseases, with biopsies 
often failing to demonstrate hemophagocytosis. 
The presence of a coexisting occult T-cell lymphoma 
further enhances the diagnostic conundrum, which 
often leads to therapeutic delay. The diagnosis of FHL 
can be established if biallelic pathological variants are 
present in any one of the following four loci: PRF1, 
UNC13D, STX11, or STXBP24 (Table 2); or if at least five 
of eight criteria listed in the guidelines of the Histiocyte 
Society are fulfilled (Table 3).11
Despite the genetic heterogeneity, patients with 
FHL have a similar phenotype. The perforin mutation 
is the most common mutation and accounts for 
20%–40% of all FHL cases. The highest reported 
percentage is among African American families 
(>50%), followed by Turkey (43%), Japan (42%), 
and India (41%).12 The mutations identified in 
those patients with the late clinical presentation 
are mostly missense compared to those harboring 
nonsense mutations.13 PRF1 encodes for the cytolytic 
effector perforin, expressed by cytolytic T-cells and 
NK-cells, which induces apoptotic cell death in 
response to granzyme.8 An abnormal perforin gene 
product results in the dysregulation of apoptotic 
mechanisms and impaired antiviral mechanisms, 
resulting in inappropriate proliferation of T-cells 
and macrophages.7,8 Malignancy-triggered HLH is 
well documented in the setting of viral infections, 
particularly EBV, where the former acts as a co-trigger. 
However, hematological malignancy co-existing with 
FHL is not well-defined, and data available in the 
literature are scarce. Mache et al.6 reported two cases 
of FHL associated with T-cell lymphoma in siblings; 
however, the genetic testing for the presence of the 
Table 2. Genetic mutations in familial hemophagocytic lymphocytosis (FHL)
Disease Gene Mutation/Protein Function
FHL-1 Not identified
FHL-2 PRF1/perforin Forms pores on target cell membrane, enabling NK-cell induced macrophage destruction
FHL-3 UNC13D/munc 13-4 Regulates cytolytic granule maturation
FHL-4 STX11/syntaxin 11 Controls cytolytic granule exocytosis
FHL-5 STXBP2/syntaxin binding protein 2 Promotes release of cytolytic granules
Table 3. Diagnostic criteria for hemophagocytic lymphohistiocytosis (HLH 2004 Protocol)
a - Molecular identification of an HLH-associated gene mutation* or
b - Five out of the eight following features:
1 - Fever ≥38.5°C
2 - Splenomegaly
3 - Peripheral blood cytopenia, with at least two of the following: hemoglobin <9 g/dL (for infants <4 weeks, 
hemoglobin <10 g/dL); platelets <100,000/mm3; absolute neutrophil count <1000/mm3
4 - Hypertriglyceridemia (fasting triglycerides >265 mg/dL) and/or hypofibrinogenemia (fibrinogen <150 mg/dL)
5 - Hemophagocytosis in bone marrow, spleen, lymph node, or liver
6 - Low or absent NK-cell activity
7 - Ferritin >500 ng/mL
8 - Elevated soluble CD25 (soluble IL-2 receptor alpha) two standard deviations above age-adjusted laboratory-specific 
norms
*Children require documentation of homozygosity or compound heterozygosity. For adults, heterozygosity of mutated 
gene is sufficient, if clinical features are compatible.
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specific FLH mutation was not performed. The present 
case presented with T-cell lymphoproliferative disorder 
(LPD) involving the thyroid, bone marrow, spleen, 
and liver, which often poses diagnostic difficulties 
in distinguishing it from EBV-HLH. The presence 
of high titers of the EBV viral-capsid antigen IgM 
probably represents a recent primary infection in this 
case, secondary to decreased immune surveillance. 
A T-cell lymphoproliferative disorder arising in the 
setting of acute EBV infection presenting with FHL is 
a rare association.14,15 Infiltrating lymphocytes can be 
morphologically bland, displaying minimal to frank 
atypia depending upon the stage of the disease. 
Interestingly, the histological atypia is proportional 
to the stage of the disease; it can be polymorphous 
and polyclonal, polymorphous and monoclonal, 
or monomorphic and monoclonal.14,15 Clonality 
studies—namely the TCR gene rearrangement and 
cytogenetic studies—differentiate LPD from EBV-HLH, 
but the major limitation relies on the detection of a 
false positive result in the reactive settings besides 
having no clinical impact on patient outcome.14,15 
Publ ished l iterature shows that EBV-HLH and 
SE-LPD share similar clinicopathological findings 
and represent a continuous spectrum of the acute 
EBV-associated T- or NK-cell lymphoproliferative 
disorders.15 FHL patients with genetic mutations 
may be prone to developing malignancy in the 
future, even if HLH resolves; therefore they require 
long-term follow-up.6,16 Our case and previous 
studies6,9,10,16 suggest that decreased perforin function 
and underlying genetic mutations lead to increased 
susceptibility for the development of HLH as well as 
lymphoma, since the pathogenesis involves common 
cytotoxic pathway mutations and possibly some 
additional genetic insult.
The treatment of HLH and FHL is focused on 
curbing the unchecked immune response and 
eliminating the trigger. HLH-94 and HLH-2004 therapy 
protocols are often not effective in FHL cases.11 
Hence, allogenic hematopoietic cell transplantation 
should be undertaken as early as possible in children 
with confirmed FHL.4,17 FHL has an aggressive clinical 
course and a fatal outcome; therefore, a high level of 
suspicion, and a thorough clinical and genetic work-up 
will prompt early diagnosis and management.
CONCLUSION
Although FHL typically manifests under 1 year 
of age, childhood and/or adult FHL is also common. 
Hematological malignancy should always be searched 
in cases with primary HLH-related genetic mutations. 
If a pathogenic mutation is identified, genetic testing 
of asymptomatic first-degree relatives should be carried 
out, and the affected individuals may be considered 
for early bone marrow transplantation before the 
development of a full-blown multi-system disorder.
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